Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: Complication of diabetes

Current Alzheimer Research

Volumn 3, Issue 3, 2006, Pages 229-235

  Mruthinti, Shyamala ^a,b   Schade, Rosann F ^a   Harrell, Dean U ^a   Gulati, Nidhi K ^c   Swamy Mruthinti, S ^d   Lee, Gregory P ^a   Buccafusco, Jerry J ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Georgia War Veterans Nursing Home   (United States)

^d UNIVERSITY OF WEST GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID; AUTOANTIBODY; CHOLINESTERASE INHIBITOR; CYTOTOXIC AGENT; IMMUNOGLOBULIN G; MEMANTINE;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; IMMUNOREACTIVITY; LINEAR REGRESSION ANALYSIS; MALE; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; STREPTOZOCIN DIABETES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CASE-CONTROL STUDIES; COGNITION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; REFERENCE VALUES;

EID: 33745630923     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506777632899     Document Type: Article

References (37)

1. Suh U-H and Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525 (2002).
2. Monnier VM, Kohn RR and Cerami A. Accelerated age related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 81: 583-587 (1984).
3. Ahmed, MU, Thorpe SR and Baynes JW. Identification of N-carboxymethyllysine as a degradation product of frucosyl lysine in glycated proteins. J Biol Chem 261: 4889-4894 (1986).
4. Hudson BI, Stickland MH and Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene. Diabetes 47: 1155-1157 (1998).
5. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc National Acad Sci (USA) 94: 5296-5301 (1997).
6. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45 (2001).
7. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Investigation 98: 1088-1094 (1996).
8. Weldon DT, Maggio JE and Mantyh PW. New insights into the neuropathology and cell biology of Alzheimer's disease. Geriatrics 52(Suppl 2): S13-S16 (1997).
9. Schmidt AM, Yan SD, Yan SF and Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111 (2000).
10. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cellular Mol Life Sci 59: 1117-1128 (2002).
11. Matsunaga N, Anan I, Forsgren S, Nagai R, Rosenberg P, Horiuchi S, et al. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathologica 104: 441-447 (2002).
12. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888: 256-262 (2001).
13. Mruthinti S, Hill WD, Swamy-Mruthinti S and Buccafusco JJ. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci 20:17-26 (2003).
14. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang M-X, et al. Autoantibodies to amyloid-β and Alzheimer's disease. Annals Neurol 49: 808-810 (2001).
15. Lopez OL, Rabin BS and Huff FJ. Serum auto-antibodies in Alzheimer's disease. Acta Neurologica Scand 84: 441-444 (1991).
16. Nath A, Hall E, Tuzova M, Dobbs M, Jones M, Anderson C, et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity NeuroMolecular Med 3: 29-39 (2003).
17. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer's disease: Increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol Aging 25: 1023-1032 (2004).
18. Wautier JL and Wautier MP. Blood cells and vascular cell interactions in diabetes. Clin Hemorheology Microcirculation 25: 49-53 (2001).
19. Stern DM, Yan SD, Yan SF and Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Reviews 1: 1-15 (2002).
20. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145: 301-308 (1997).
21. Ott A, Stolk RP, van Harskamp F, Grobbee DE and Breteler MM. Associate of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 39: 1392-1397 (1996).
22. Luchsinger JA, Tang MX, Stern Y, Shea S and Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-641 (2001).
23. Peila R, Rodriguez BL and Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51(4):1256-1262 (2002).
24. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA and Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666, (2004).
25. Perry RE, Swamy MS and Abraham EC. Progressive changes in lens crystallin glycation and high-molecular weight aggregate formation leading to cataract development in streptozotocin-diabetic rats. Exp Eye Res 44: 269-282 (1987).
26. Münch G, Mayer S, Michaeis J, Hipkiss AR, Riederer P, Müller R, et al. Biochim Biophys Acta 1360: 17-29 (1997).
27. Messier C, Awad N and Gagnon M. The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia. Neurological Res 26: 567-57 (2004)2.
28. Launer LJ. Diabetes and brain aging: epidemiologic evidence. Current Diabetes Reports 5: 59-63 (2005).
29. Awad N, Gagnon M and Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin ExpNeuropsychol 26: 1044-1080 (2004).
30. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 64 Suppl 9: 11-17 (2003).
31. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP and van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. Br Med J 331: 321-327 (2005).
32. Linton P and Thoman ML. T cell senescence. Frontiers Biosci 6: D248-D261 (2001).
33. Ha C and Park CB. Template-directed self-assembly and growth of insulin amyloid fibrils. Biotechnol Bioengineering 90: 848-855 (2005).
34. D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Medical Hypotheses 64: 458-463 (2005).
35. Deane R, Yan SD, Submamaaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nature Med 9: 907-914 (2003).
36. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741: 199-205 (2005).
37. Stuchbury G and Münch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transmission 112: 429-453 (2005).